121 related articles for article (PubMed ID: 31999934)
1. Bone dynamics and inflammation: lessons from rare diseases.
Matsumoto Y; Rottapel R
Immunol Med; 2020 Jun; 43(2):61-64. PubMed ID: 31999934
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of B-cell receptor signaling by a point mutation of adaptor protein 3BP2 identified in human inherited disease cherubism.
Ogi K; Nakashima K; Chihara K; Takeuchi K; Horiguchi T; Fujieda S; Sada K
Genes Cells; 2011 Sep; 16(9):951-60. PubMed ID: 21794028
[TBL] [Abstract][Full Text] [Related]
3. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
Levaot N; Voytyuk O; Dimitriou I; Sircoulomb F; Chandrakumar A; Deckert M; Krzyzanowski PM; Scotter A; Gu S; Janmohamed S; Cong F; Simoncic PD; Ueki Y; La Rose J; Rottapel R
Cell; 2011 Dec; 147(6):1324-39. PubMed ID: 22153076
[TBL] [Abstract][Full Text] [Related]
4. PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism.
Matsumoto Y; Rottapel R
Trends Mol Med; 2023 May; 29(5):390-405. PubMed ID: 36948987
[TBL] [Abstract][Full Text] [Related]
5. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.
Levaot N; Simoncic PD; Dimitriou ID; Scotter A; La Rose J; Ng AH; Willett TL; Wang CJ; Janmohamed S; Grynpas M; Reichenberger E; Rottapel R
J Clin Invest; 2011 Aug; 121(8):3244-57. PubMed ID: 21765218
[TBL] [Abstract][Full Text] [Related]
6. Adaptor protein 3BP2 and cherubism.
Hatani T; Sada K
Curr Med Chem; 2008; 15(6):549-54. PubMed ID: 18336269
[TBL] [Abstract][Full Text] [Related]
7. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
8. [The adaptor protein 3BP2 in leukocyte signaling].
Deckert M
Med Sci (Paris); 2006 Dec; 22(12):1081-6. PubMed ID: 17156730
[TBL] [Abstract][Full Text] [Related]
9. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
10. Point mutations of 3BP2 identified in human-inherited disease cherubism result in the loss of function.
Miah SM; Hatani T; Qu X; Yamamura H; Sada K
Genes Cells; 2004 Nov; 9(11):993-1004. PubMed ID: 15507112
[TBL] [Abstract][Full Text] [Related]
11. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
12. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
13. Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Morice A; Joly A; Ricquebourg M; Maruani G; Durand E; Galmiche L; Amiel J; Vial Y; Cavé H; Belhous K; Piketty M; Cohen-Solal M; Berdal A; Collet C; Picard A; Coudert AE; Kadlub N
BMC Musculoskelet Disord; 2020 Aug; 21(1):564. PubMed ID: 32825821
[TBL] [Abstract][Full Text] [Related]
14. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
15. The 3BP2 adapter protein is required for chemoattractant-mediated neutrophil activation.
Chen G; Dimitriou I; Milne L; Lang KS; Lang PA; Fine N; Ohashi PS; Kubes P; Rottapel R
J Immunol; 2012 Sep; 189(5):2138-50. PubMed ID: 22815290
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism.
Ueki Y; Tiziani V; Santanna C; Fukai N; Maulik C; Garfinkle J; Ninomiya C; doAmaral C; Peters H; Habal M; Rhee-Morris L; Doss JB; Kreiborg S; Olsen BR; Reichenberger E
Nat Genet; 2001 Jun; 28(2):125-6. PubMed ID: 11381256
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.
Carvalho VM; Perdigão PF; Pimenta FJ; de Souza PE; Gomez RS; De Marco L
Oral Oncol; 2008 Feb; 44(2):153-5. PubMed ID: 17368082
[TBL] [Abstract][Full Text] [Related]
18. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
19. Syk-dependent tyrosine phosphorylation of 3BP2 is required for optimal FcRγ-mediated phagocytosis and chemokine expression in U937 cells.
Chihara K; Kato Y; Yoshiki H; Takeuchi K; Fujieda S; Sada K
Sci Rep; 2017 Sep; 7(1):11480. PubMed ID: 28904407
[TBL] [Abstract][Full Text] [Related]
20. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Luci C; Vieira E; Bourinet M; Rousseau D; Bonnafous S; Patouraux S; Lefevre L; Larbret F; Prod'homme V; Iannelli A; Tran A; Anty R; Bailly-Maitre B; Deckert M; Gual P
Cell Mol Gastroenterol Hepatol; 2022; 13(1):173-191. PubMed ID: 34411785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
